- Went public, Feb 2011
- Raised $15M funding round, Jan 2021
- Raised $5.5M funding round, Feb 2015
About
IceCure is transforming healthcare with the choice of advanced minimally invasive cryoablation for benign and malignant tumors in women's health and interventional oncology. The FDA cleared and CE marked ProSense® System uses liquid-nitrogen (LN2) to generate ultra cold temperatures to destroy tumors by freezing them and is supported by clinical experience across multiple areas of cancer care.
Unlike surgical removal of a tumor, cryoablation is less invasive as only a thin, needle-like cryoprobe is placed into the tumor, no tissue is removed, and it is performed under local anesthesia or light sedation. Under imaging guidance (ultrasound or CT), LN2 enters the close-looped cryoprobe needle and a lethal ice ball forms around the targeted tissue. The destroyed tissue undergoes a necrotic process, to naturally remove the ablated cells over time, without needing to surgically remove it.
IceCure led the ICE3 clinical trial on cryoablation of early-stage, low-risk breast cancer, one of the largest studies of its kind. The ICE3 demonstrated a 96.3% recurrence-free rate for early-stage, low-risk breast cancer patients who underwent ProSense cryoablation with endocrine therapy. Patients and physicians reported a high level of satisfaction with the cosmetic results, as only a small nick is made in the skin to insert the cryoprobe and the breast remains whole. An FDA panel voted favorably on ProSense's benefit-risk profile in November 2024.
The ICESECRET study interim results for the destruction of kidney tumors has shown IceCure's ProSense® cryoablation system to be safe and effective in the destruction of kidney tumors with 88.7% recurrence-free rate.
ProSense® currently has FDA clearance for use as a cryosurgical tool in the destruction of fibroadenomas and in the fields of general surgery, thoracic surgery, gynecology, oncology, proctology, and urology. The system is CE-marked and is available across several European and East Asian countries, Brazil, and India.
Funding history · 5 rounds · $71.5M total
Q&A
- What is IceCure Medical's primary focus?
- IceCure Medical focuses on transforming healthcare with advanced minimally invasive cryoablation for benign and malignant tumors, particularly in women's health and interventional oncology.
- What is the ProSense® System?
- The ProSense® System is IceCure Medical's FDA-cleared and CE-marked cryoablation system that uses liquid nitrogen to destroy tumors by freezing them. It is used in general surgery, thoracic surgery, gynecology, oncology, proctology, and urology.
- What were the key findings of IceCure's ICE3 clinical trial?
- The ICE3 clinical trial, one of the largest studies on cryoablation for early-stage, low-risk breast cancer, demonstrated a 96.3% recurrence-free rate for patients who underwent ProSense cryoablation with endocrine therapy. An FDA panel voted favorably on ProSense's benefit-risk profile in November 2024.
- What are the results of the ICESECRET study for kidney tumors?
- Interim results from the ICESECRET study for the destruction of kidney tumors showed IceCure's ProSense® cryoablation system to be safe and effective, with an 88.7% recurrence-free rate.
- When did IceCure Medical receive FDA marketing authorization for ProSense® Cryoablation for low-risk breast cancer?
- IceCure Medical received FDA marketing authorization for ProSense® Cryoablation for the treatment of low-risk breast cancer in women aged 70 and above in October 2025.
- What was a significant regulatory approval for IceCure Medical in Brazil?
- In September 2023, IceCure Medical's ProSense Cryoablation System received regulatory approval in Brazil.
- What is the status of IceCure Medical's next-generation XSense™ Cryoprobes?
- In September 2025, IceCure Medical was granted a Notice of Allowance for a U.S. Patent for its next-generation XSense™ Cryoprobes. Additionally, in July 2024, the U.S. FDA granted regulatory clearance for the next-gen XSense™ Cryoablation System with CryoProbes.
- What was the outcome of the FDA Advisory Panel meeting for ProSense® in early-stage, low-risk breast cancer?
- In November 2024, an FDA advisory panel voted in favor of IceCure's ProSense cryoablation benefit-risk profile for early-stage, low-risk breast cancer.
- What was a recent financial event for IceCure Medical?
- In March 2026, IceCure Medical announced the pricing of a $4.0 million registered direct offering and concurrent private placement.
- What is the current employee count for IceCure Medical?
- IceCure Medical has 51-200 employees.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
Identifiers & details
| Founded | 2006-1 |
|---|---|
| Employees (exact) | 66 |
| Offices | Nanuet |
| Market cap | $42.1M |
| Status reason | Public on TASE on Feb 2011;Public on NASDAQ on Aug 2021; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2011-02 | ||||
| 2013-08 | ||||
| 2019-02 | ||||
| 2020-08 | ||||
| 2021-08 | ||||
| 2021-12 | ||||
| 2022-12 |